Key terms

About CRBP

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CRBP news

Mar 27 4:55am ET Corbus Pharmaceuticals management to meet with Oppenheimer Mar 25 7:48am ET Corbus Pharmaceuticals management to meet with Oppenheimer Mar 13 4:53pm ET Corbus Pharmaceuticals files $300M mixed securities shelf Mar 13 7:26am ET Corbus Pharmaceuticals price target raised to $58 from $51 at Oppenheimer Mar 12 8:32am ET Corbus Pharmaceuticals Shares Informal Financial Snapshot Mar 12 8:04am ET Corbus Pharmaceuticals sees cash runway through March 31, 2027 Mar 12 8:04am ET Corbus Pharmaceuticals reports Q4 EPS ($1.81) vs. ($2.61) last year Mar 06 8:30am ET One new option listing on March 6th Mar 06 7:54am ET Corbus Pharmaceuticals upgraded to Buy from Hold at Jefferies Feb 28 8:05am ET Corbus Pharmaceuticals appoints Smethurst as CMO Feb 07 4:36am ET Corbus Pharmaceuticals Announces Chief Scientific Officer Resignation Feb 06 4:19am ET Corbus Pharmaceuticals Shares Updated Corporate Insights Jan 31 9:21am ET Corbus prices 4.33M shares at $19.00 in underwritten public offering Jan 30 7:00pm ET Corbus Pharmaceuticals offers to sell common stock, no amount given Jan 29 8:12am ET Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Corbus Pharmaceuticals (CRBP) Jan 27 4:04am ET Corbus Pharmaceuticals’ Promising Phase 1 Cancer Trial Results Jan 27 4:04am ET Corbus Pharmaceuticals Unveils Phase 1 Trial Results Jan 26 9:39am ET Corbus Pharmaceuticals trading resumes Jan 26 9:34am ET Corbus Pharmaceuticals trading halted, volatility trading pause Jan 26 7:32am ET Corbus Pharmaceuticals announces data from study of CRB-701 Jan 23 8:14am ET Corbus Pharmaceuticals to present Phase 1 clinical data for SYS6002 Jan 09 8:03am ET Corbus Pharmaceuticals announces FDA clearance of IND application of CRB-601

No recent news articles are available for CRBP

No recent press releases are available for CRBP

CRBP Financials

1-year income & revenue

Key terms

CRBP Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CRBP Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms